Laxoberal

Sodium picosulfate, the active ingredient in Laxoberal, is a stimulant laxative presented as an oral formulation for oral use. It is used to relieve constipation and to prepare the bowel before diagnostic procedures. GNH USA supplies Laxoberal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laxoberal, a stimulant laxative, acts on the lower gastrointestinal tract to promote bowel movements in several clinical situations.

Constipation: provides relief by stimulating colonic peristalsis in patients with functional or opioid‑induced constipation. Bowel cleansing prior to diagnostic procedures: facilitates rapid evacuation of the colon before colonoscopy, sigmoidoscopy or radiologic imaging.

Laxoberal may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Abdominal cramps or discomfort - Diarrhea or loose stools - Nausea or mild vomiting - Flatulence or bloating - Urgency to defecate - Mild electrolyte imbalance (e.g., low potassium)

Serious or Rare Side Effects: - Severe dehydration - Marked electrolyte disturbances (e.g., hyponatremia) - Allergic reactions such as rash or angioedema - Colonic perforation - Persistent severe abdominal pain

Before prescribing Laxoberal, clinicians should consider several safety aspects. - Assess bowel function: confirm presence of constipation and rule out obstruction. - Avoid in acute abdominal pain or suspected mechanical blockage. - Use with caution in patients with electrolyte disorders or renal impairment. - Do not exceed recommended duration: prolonged use may cause dependence. - Pediatric use: limit to children under medical supervision. - Store at room temperature: keep in the original pack, protect from moisture.

Laxoberal can interact with other medications that affect gastrointestinal motility or electrolyte balance.

Major Interactions (Avoid): - Concurrent use of other stimulant laxatives or high‑dose mineral oil. - Loop or thiazide diuretics: risk of additive electrolyte loss. - Cardiac glycosides: potential for arrhythmia due to potassium depletion.

Moderate Interactions (Monitor Closely): - NSAIDs: increased risk of gastrointestinal irritation. - Antidepressants (e.g., SSRIs): may enhance serotonergic effects on gut motility. - Oral rehydration solutions: monitor electrolyte status when used together.